Cellumed Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 10:11 am IST
Share
Cellumed Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 104.96 million compared to KRW 5,871.47 million a year ago. Net income was KRW 2,929.84 million compared to KRW 176.8 million a year ago. Basic earnings per share from continuing operations was KRW 76 compared to KRW 6 a year ago. Diluted earnings per share from continuing operations was KRW 76 compared to KRW 6 a year ago. Basic earnings per share was KRW 74 compared to KRW 6 a year ago.
For the nine months, sales was KRW 257.14 million compared to KRW 6,846.43 million a year ago. Net income was KRW 2,714.25 million compared to net loss of KRW 1,395.76 million a year ago. Basic earnings per share from continuing operations was KRW 70 compared to basic loss per share from continuing operations of KRW 52 a year ago. Diluted earnings per share from continuing operations was KRW 70 compared to diluted loss per share from continuing operations of KRW 52 a year ago. Basic earnings per share was KRW 70 compared to basic loss per share of KRW 52 a year ago.
CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.
CELLUMED CO.,LTD. 
